Glucose and glutamine are the two principal nutrients that cancer cells use to proliferate and survive. Many cancers show altered glucose metabolism, which constitutes the basis for in vivo positron emission tomography (PET) imaging with 18
INTRODUCTION
Cancer cells commonly undergo metabolic reprogramming, enabling increased nutrient uptake and metabolism (1) . Glucose and glutamine are key nutrients that cancer cells use for survival and proliferation (1, 2) . Through the Warburg effect, tumors exhibit enhanced glucose uptake and metabolism by aerobic glycolysis (1, 2) . This increase in glucose uptake can be evaluated in vivo using positron emission tomography (PET) imaging with the glucose analog 18 F-fluorodeoxyglucose ( 18 F-FDG). 18 F-FDG PET imaging is a valuable clinical tool and is routinely used in diagnosing, grading, and staging cancers and in assessing the efficacy of therapies (3) . However, 18 F-FDG is not effective in evaluating gliomas in vivo because the high glucose metabolism in the normal brain results in suboptimal tumor detection and delineation (4, 5) . Neurologically destructive gliomas are one of the most fatal forms of cancer. Thus, there is an urgent and unmet need to develop more effective clinical imaging modalities as a means to effectively and noninvasively evaluate altered nutrient uptake and metabolism in gliomas in vivo.
Glutamine is the other principal nutrient that tumor cells use. It is the most abundant amino acid in the plasma, and many cancers are addicted to glutamine for their survival. Cancers such as neuroblastoma, lymphoma, renal carcinoma, and pancreatic adenocarcinoma use altered glutamine metabolism to support their growth and survival. Glutamine metabolism contributes to tumor cell proliferation, ATP (adenosine 5′-triphosphate) synthesis, and the production of biomolecules, such as proteins, lipids, and nucleic acids (6, 7) . We have recently developed [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] F-(2S,4R)-fluoroglutamine ( 18 F-FGln), an analog of glutamine that is taken up by cancer cells in vitro and shows specific uptake on PET imaging in mouse xenograft models in vivo (8) .
We hypothesized that glutamine addiction in gliomas can be leveraged to image gliomas in vivo by PET with 18 F-FGln to assess altered nutrient uptake in the tumors. Primary glioblastomas (GBMs) show various genetic alterations, such as platelet-derived growth factor receptor A (PDGFRA) amplification, phosphatase and tensin homolog (PTEN) loss, and epidermal growth factor (EGFR) alterations (9) . These molecular abnormalities converge on deregulation of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway (9) . Secondary GBMs and~70% of intermediate-grade gliomas harbor mutations in isocitrate dehydrogenase 1 (IDH1), an enzyme in the tricarboxylic acid (TCA) cycle, resulting in the production of the oncometabolite 2-hydroxyglutarate (2-HG) (10) . Thus, from a metabolic perspective, gliomas fall into two broad groups: those driven by enhanced PI3K/AKT/mTOR signaling (primary GBMs) and those bearing IDH1 mutations (secondary GBMs and intermediate-grade gliomas).
To address our hypothesis, we used PET imaging with 18 F-FGln in vivo to evaluate glutamine uptake in PDGF (platelet-derived growth factor)-driven glioma models with PTEN loss (to model primary GBMs with enhanced PI3K/AKT/mTOR signaling) and in IDH1-mutant (IDH1m) glioma models. The data demonstrate that 18 F-FGln showed high uptake in both glioma models but minimal uptake in the normal brain, enabling clear tumor visualization. Further, 18 F-FGln specifically delineated gliomas in vivo by PET imaging in animal models and in human glioma patients with disease progression. The results suggest that 18 F-FGln may serve as a valuable clinical tool in the assessment of metabolic nutrient uptake in gliomas in vivo using PET imaging.
RESULTS

18
F-FGln shows high uptake in gliomas but negligible uptake in the normal brain Because glutamine is an important source of replenishment of TCA cycle metabolites (termed anaplerosis) in many cancers, we first evaluated the contribution of glutamine to TCA cycle anaplerosis in glioma cell lines bearing various oncogenes: U87-MG (PTEN −/− ), TS543 (PDGFRA, PTEN −/− ), and TS603 (IDH1m). Glutamine was the main TCA cycle anaplerotic substrate in all cell lines tested ( fig. S1 ), underscoring the importance of glutamine as a key nutrient in gliomas and the rationale for developing glutamine-based PET imaging of gliomas. F-FGln PET imaging is mainly a measure of glutamine uptake.
To assess glutamine uptake in vivo in gliomas, we used PET imaging with the glutamine analog 18 F-FGln (Fig. 1A) . Biodistribution studies with 18 F-FGln in normal mice ( fig. S3 ) showed that 18 F-FGln crossed the blood-brain barrier (BBB) but showed minimal uptake in the normal brain compared to other organs such as the pancreas and the gut ( Fig. 1 and  fig. S3 ). We thus postulated that high glutamine utilization in gliomas ( fig. S1 ) coupled with minimal uptake in the normal brain ( Fig. 1 and fig. S3 fig. S3 ). All glioma subcutaneous xenografts showed significantly (P < 0.0001) higher uptake of 18 F-FGln compared to the normal brain ( Fig. 1 and fig. S6 , whole body images). 18 F-FDG showed higher or equivalent uptake in the normal brain compared to all tested glioma subcutaneous xenografts ( Fig. 1 and fig. S6 , whole-body images).
In IDH1m glioma cells, we found that [U- 13 C]glutamine was metabolized to generate the oncometabolite 2-HG. This was reversed either by short hairpin RNA (shRNA) knockdown of total IDH1 (mutant and wild type) or by an IDH1m-specific inhibitor (IDH35) (11) in vitro (figs. S1I and S7). Glioma xenografts bearing shRNA against total IDH1 did not show significant alterations in 18 F-FGln uptake compared to controls ( fig. S7 ). This suggests that 18 F-FGln uptake in vivo in TS603 IDH1m cells is not altered when the activity of mutant IDH1 generating 2-HG is inhibited ( fig. S7 ).
F-FGln enables distinct delineation of gliomas in vivo
We next evaluated well-characterized genetically engineered glioma mouse models using the RCAS (replication-competent avian sarcomaleukosis virus long terminal repeat with splice acceptor)/tv-a (tumor F-FGln uptake at 0.5, 1, and 2 hours after injection in the normal brain (black bars, n = 6 for all time points) with glioma xenografts: TS598 with EGFR amplification (green bars, n = 6 for all time points), U87-MG with PTEN deletion (dark blue bars, n = 5 for all time points), TS543 with PDGFRA amplification and PTEN deletion (light blue bars, n = 5 for 0.5-and 1-hour time points, n = 4 for 2-hour time point), and TS603 with IDH1 R132H mutations (orange bars, n = 5 for all time points). %ID/cc: percent injected dose/cubic centimeter. Statistical significance was determined by two-sided analysis of variance (ANOVA); ***P < 0.001. (C) Comparison of 18 F-FDG uptake at 0.5, 1, and 2 hours after injection in the normal brain (black bars, n = 6 for all time points) with glioma xenografts: TS598 with EGFR amplification (green bars, n = 3 for 0.5 and 1 hour time points and n = 6 for 2-hour time point), U87-MG with PTEN deletion (dark blue bars, n = 5 for all time points), TS543 with PDGFRA amplification and PTEN deletion (light blue bars, n = 6 for 0.5-hour time point and n = 4 for 1-and 2-hour time points), and TS603 with IDH1 R132H mutations (orange bars, n = 5 for all time points). %ID/cc: percent injected dose/cubic centimeter. ), which develop GBM histologically identical to human GBM ( fig. S4 , E and G) (12) . PET imaging in these animals showed marked 18 F-FGln uptake with distinct tumor delineation (compared to the surrounding brain) in a region directly corresponding to the tumor, as detected by magnetic resonance imaging (MRI) and confirmed by autoradiography and histopathology (Fig. 2, A to F) . Tumor-to-background ratios with 18 F-FGln ranged from 4:1 to 6:1, compared to~1:1 tumor-to-background ratio with 18 F-FDG (Fig. 2F) . Similar findings were observed in RCAS-PDGF animals on a PTEN wild-type background ( fig. S8 , A to D) and in an orthotopic IDH1m glioma model (Fig. 2, G to L, and fig.S8 , E to G). 18 F-FGln uptake is not observed in neuroinflammation or BBB disruption To evaluate if inflammatory cells contributed to 18 F-FGln uptake, we created mouse models of neuroinflammation (Fig. 3A) . Lipopolysaccharide (LPS) injection into the brain resulted in global activation of IBA1 immunoreactive microglia/macrophages in the injected hemisphere well beyond the injection site ( Fig. 3B and fig. S9 , A to D). We also used interferon-g (IFN-g), which polarizes macrophages/microglia toward classic activation, and interleukin-4 (IL4), which mediates an alternative activation phenotype similar to tumor-associated macrophages (13) . Robust neuroinflammation was confirmed histopathologically (Fig.  3B and fig. S9 , A to D). Mice were imaged at the peak of neuroinflammation with 18 F-FGln and 18 F-FDG (Fig. 3, C to E, and fig. S9 , E to G). 18 F-FDG PET is generally a poor measure of neuroinflammation in mouse brains in vivo because of the high background uptake in the brain (14) . Consistent with this, no lesion was discernible with 18 F-FDG PET (Fig. 3D and fig. S9F ). Conversely, 18 F-FGln did not show any uptake at the site of the lesion in neuroinflammatory models, as opposed to the high uptake seen in gliomas (Fig. 3C and fig. S9E ).
To address the concern of BBB permeability as a factor in causing increased 18 F-FGln delivery to the brain, we used an adenosine receptor agonist that is an established means of increasing BBB permeability by increasing spaces between endothelial cells in brain capillaries (15, 16) .
a combined A1 and A2 adenosine receptor agonist, significantly (P = 0.034) increased BBB permeability in mice as determined by measuring extravasation of fluorescentlabeled dextran into the brain (Fig. 3, F and G). We did not see increased 18 F-FGln delivery to the brain in NECA-treated animals ( Fig. 3 , H to K), suggesting that increased BBB permeability by itself does not artificially increase 18 F-FGln delivery to the brain. This demonstrates that neuroinflammation or a breach in the BBB using NECA does not significantly contribute to 18 F-FGln uptake.
18
F-FGln uptake in gliomas is reduced after chemo/radiation therapy To evaluate if 18 F-FGln can monitor treatment efficacy and differentiate tumor from posttreatment changes, we studied a wellcharacterized RCAS-PDGF, PTEN-null mouse model of radiation/chemotherapy (17) (Fig. 4A and fig. S10 , A to C). The same mouse was imaged before therapy and after treatment with MRI, 18 F-FGln, and 18 F-FDG (Fig. 4, B to F) . As can be seen in posttreatment changes in human patients, the T2-weighted MRI showed no appreciable differences when comparing before-treatment scans with after-treatment scans (18) . In contrast, 18 F-FGln showed a significant reduction (P = 0.0078) in tumor uptake after treatment, which was confirmed by autoradiography (Fig. 4, C to F) .
To assess the mechanism by which chemo/radiation therapy results in a decrease in 18 F-FGln uptake, we compared before-treatment and aftertreatment glioma brain tissues. Tumor burden was dramatically reduced after treatment, as demonstrated by a reduction in the Olig2-positive tumor cells (P = 0.031) (fig. S10, A and B) . Brain tissues after treatment showed increased reactive gliosis in the form of GFAP (glial fibrillary acidic protein)-positive astrocytosis and abundant IBA1-positive macrophages/microglia ( fig. S11, A and B) . No significant changes were noted in CD3-positive lymphocyte infiltration or in blood vessels as delineated by CD31 staining for endothelial cells and collagen staining for vessel walls ( fig. S11, C to E) . Moreover, expression of the glutamine transporter SLC1A5 in residual tumor cells after treatment was not significantly different from that seen in tumor cells before treatment ( fig. S11F ). These data suggest that reduction in 18 F-FGln uptake after chemo/radiation therapy is due to a decrease in tumor burden. Further, these data imply that F-FDG (red bars) illustrates differences in background uptake with both ligands in normal brain (top panel) and tumor-to-brain ratios from three clinically stable glioma patients and three glioma patients with clinically progressive disease (bottom panel) (see tables S1 and S2 for details). For all graphs, data are represented as means ± SEM.
F-FGln shows high tumor-to-brain uptake ratio in human gliomas with progression
To determine if our findings could be translated to a spectrum of human gliomas apart from the animal models studied, we evaluated the expression of the glutamine transporter SLC1A5, which in part mediates 18 F-FGln uptake (8, 19) , as demonstrated by siRNA (small interfering RNA) knockdown and pharmacologic inhibition ( fig. S12, A  and B) . Immunohistochemistry in normal brain tissue samples (n = 8, fig. S12C ) showed minimal expression, mirroring low background 18 F-FGln uptake. In contrast, SLC1A5 demonstrated higher expression in various gliomas (n = 64), consistent with high 18 F-FGln glioma uptake ( fig. S12, C and D) . Further, we queried the GBM Cancer Genome Atlas for SLC1A5 mRNA expression, which was noted in all GBM subtypes ( fig. S12E ). These data suggest that 18 F-FGln uptake is not restricted to the animal model glioma genotypes tested and may be of broader use in evaluating uptake of glutamine as a key nutrient in gliomas.
We translated these findings in vivo to human glioma subjects as an initial investigation of 18 F-FGln PET imaging in human cancer patients [phase 1 study; Fig. 5 (A to L) and figs. S13, S14 (A to C), and S15 (A to C)]. As part of this study, we compared 18 F-FGln uptake in three glioma patients with clinical progression of disease and three patients with stable disease (tables S1 and S2). Normal brain parenchyma showed minimal 18 F-FGln uptake, and 18 F-FGln avidity was noted in all tumors that showed progression within the three patients (tumor/brain ratio range: 3.7 to 4.8; Fig. 5L, fig. S14 , and tables S2 and S3). In contrast, clinically stable tumors showed minimal or no (Fig.  5C , three red arrows) from the surrounding brain, but not the anterior part (two red arrows, Fig. 5C ). In contrast, both regions of the tumor showed high uptake with 18 F-FGln (Fig. 5, B and E) . This is an important issue considering the infiltrative nature of gliomas. Further, this patient's tumor demonstrated mild contrast enhancement on gadoliniumenhanced MRI (Fig. 5A ), but high 18 F-FGln avidity (Fig. 5, B and E) and retention of 18 F-FGln compared to its rapid clearance in the blood (Fig. 5F ). Whole-body PET images, plasma and blood time-activity curves, biodistribution, tracer metabolite analysis, and dosimetry from these glioma patients are provided in the Supplementary Materials (figs. S14 to S16 and tables S3 to S5). These findings in human subjects recapitulate our 
DISCUSSION
The two principal nutrients that cancers depend on are glucose and glutamine, and metabolism of these nutrients through glycolysis and glutaminolysis is vital for cancer survival and growth (1, 2) . We aimed specifically to develop a means of noninvasively assessing nutrient uptake in gliomas. 18 F-FDG as a measure for metabolic glucose uptake is ineffective in gliomas because of the high background in the surrounding brain. To begin to address this gap in our knowledge, we examined whether glutamine addiction displayed by many cancer cells can be leveraged to detect glutamine uptake in gliomas in vivo using F-FGln uptake is mainly mediated by the amino acid transporter SLC1A5 (8, 19) , which was minimally expressed in the normal brain but markedly increased in gliomas. GC-mass spectroscopy analysis showed that FGln was not metabolized to F-glutamate. Further, we have previously shown that 60 to 70% of 18 F-FGln is incorporated into protein (8, 19) , and we now suggest a model wherein 18 F-FGln is taken up mainly by SLC1A5 and is trapped in glioma cells by incorporation into proteins.
As part of our human trial of F-FGln compared to rapid clearance in the blood. If the tumor activity on PET was merely due to BBB breakdown, the data plot would instead demonstrate progressive clearance of tracer from the tumor region, in parallel with tracer clearance from the blood pool. Although we cannot entirely rule out the effects of BBB alteration, human and animal data together suggest that the relatively high 18 F-FGln avidity in gliomas is not solely a function of tumor BBB disruption.
A limitation of this study is that the isotope shows bone uptake in animal models and humans (including axial uptake), with free fluorine-18 detected in the blood of all patients, implying that in vivo defluorination occurs. Peripheral bony uptake was minimal compared to axial uptake, suggesting uptake by bone marrow cells. To evaluate the impact of free fluoride on organ uptake of 18 F-FGln, we compared the biodistribution of 18 F-sodium fluoride as a control with that of 18 F-FGln. 18 F-sodium fluoride showed high bony uptake, but free fluoride uptake within various organs, including the brain, was minimal. In contrast, 18 F-FGln showed lower bony uptake, but higher uptake in all organs compared to 18 F-sodium fluoride. These data suggest that free fluoride does not majorly contribute to specific uptake of 18 F-FGln within various organs. Moreover, tracer uptake in the skull did not obscure glioma 18 F-FGln PET evaluations, because gliomas are restricted to the brain and do not invade the skull or metastasize to bone. Another limitation is the small sample size of the glioma subjects assessed. However, despite this small sample size, data from human subjects closely mirror data from glioma cell lines and animal models, as evidenced by high 18 F-FGln glioma uptake and low avidity in the surrounding brain. Further, one of the prerequisites of the Food and Drug Administration (FDA)-approved, human microdose, open-label, phase 1 trial was for every patient to have a tissue diagnosis prior to imaging. This precluded imaging any surgerynaïve patients. Despite these limitations, the data presented support an exploratory proof-of-principle concept that 18 F-FGln could be potentially used as an imaging agent in glioma patients.
Noninvasive imaging forms an integral part of the clinical management of glioma patients. T1-weighted MRI with or without gadolinium is the current neuroimaging standard in glioma assessment (20) . MRI provides vital anatomic and structural information and is helpful in characterizing tumors using FLAIR (fluid-attenuated inversion recovery) and in assessing BBB disruption using gadolinium contrast enhancement, but it does not provide information on nutrient uptake and metabolism. Newer modalities such as magnetic resonance spectroscopy or perfusion/diffusion-weighted MRI are beginning to address these limitations (21, 22) . PET imaging agents such as [ F-FSPG) as a PET tracer has been described in preclinical models and human subjects (25, 26) . This tracer relies on the xCT cysteine/glutamate exchanger system and is thought to label intracellular glutamate pools (25) . Our goal is to translate a specific nutrient metabolic pathway that is biologically relevant to the pathology of gliomas to a clinically useful imaging modality. Indeed, 18 F-FGln PET imaging takes advantage of glutamine addiction in gliomas and may serve as a valuable tool to assess metabolic glutamine uptake in gliomas in vivo. Low uptake in the normal brain may also help in evaluating central nervous system metastasis.
Mice treated with chemo/radiation therapy showed a profound reduction in 18 F-FGln uptake after treatment, corresponding to a decrease in tumor volume. Brain vasculature (CD34-positive and collagen IVpositive blood vessel walls) did not differ before and after treatment. Although these data suggest that vasculature may not be altered in this model, we cannot entirely rule out other changes in the vasculature or the BBB that may contribute to reduced 18 F-FGln uptake after treatment. However, neuroinflammatory models showed no 18 F-FGln uptake and, together with reduced uptake after treatment, suggest that 18 F-FGln may be potentially useful in differentiating nonneoplastic, posttreatment, and inflammatory changes from tumor. Data from our small sample size of patients suggest that 18 F-FGln may also be useful in monitoring progression of gliomas as they transform to more metabolically active and aggressive tumors. In summary, the studies suggest that glutamine-based PET imaging with 18 F-FGln may be an important measure of glutamine uptake in gliomas in vivo and may serve as a valuable tool in the clinical management of gliomas.
MATERIALS AND METHODS
Study design
The objective of this study was to address the clinically unmet need of assessing metabolic nutrient uptake in gliomas in vivo. This goal was addressed by (i) evaluating glutamine uptake in gliomas by PET imaging in clinically relevant glioma animal models, (ii) assessing if glutamine PET-based imaging could monitor therapeutic response in glioma animal models, and (iii) translating these findings to human subjects.
All animal experiments were performed after approval from the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Animal Care and Use Committee and were conducted as per National Institutes of Health (NIH) guidelines for animal welfare. The use of glutamine-based PET imaging to monitor therapeutic response was assessed using standard chemo/radiation therapy protocols in glioma animal models. Animals were randomly assigned to various test groups in a blinded manner. Individuals handling the animals and conducting animal surgeries and therapies were blinded to the experimental design. Evaluation of 18 F-FGln PET uptake measurements in animals was performed in a nonblinded fashion. Because 18 F-FGln microPET imaging is a new imaging technology, it is difficult to estimate sample size with adequate power. An n = 3 to 9 was selected for these well-controlled models with a low (<10%) error in consecutive studies. Cell culture studies were conducted using three independent experiments (27) . No samples or animals were excluded from data analyses.
Human glioma subjects were studied as part of an in-human microdose, open-label, phase 1 trial of 18 F-FGln PET that was approved by the institutional review board and conducted under the auspices of an FDAapproved investigational new drug application in compliance with the Standards for Reporting of Diagnostic Accuracy studies (STARD) guidelines for diagnostic studies (trial registered at www.clinicaltrial.gov; NCT01697930). Informed consent was obtained before imaging.
Animal models of gliomas
Subcutaneous glioma xenografts were created by inoculating SCID mice (4 to 6 weeks of age, male and female, nonobese diabetic (NOD)-SCID, Taconic Farms Inc.) with 1 × 10 6 U87-MG, TS603, TS543, or TS598 cells resuspended in 200 ml of a 1:1 volume of cell culture medium and Matrigel (BD Biosciences). Animals were imaged when xenograft tumor volumes approached 200 mm 3 . Genetically modified glioma models were generated using the RCAS/tv-a system. Four-to 6-week-old, male or female C57BL6 Nestin-tv-a/Ink4a-Arf −/− mice with or without a PTEN fl/fl background were anesthetized by injection of ketamine (0.1 mg/g) and xylazine (0.02 mg/g), using a stereotactic fixation device (Stoelting) (17) . One microliter of RCAS-PDGF or a 1:1 mixture of 4 × 10 4 RCAS-PDGF and RCAS-Cre-transfected DF1 cells was delivered using a 30-gauge needle attached to a Hamilton syringe. Cells were injected into the right frontal cortex [stereotactic coordinates: bregma +1.7 mm (anterior), lateral −0.5 mm (right), and at a depth of 2.5 mm]. For orthotopic injection of glioma cells, the same procedure was followed, except that TS603 IDH1m (1 × 10 6 cells) was implanted into the right frontal cortex (same coordinates as above). Individuals performing implantation and stereotactic injections were blinded to the experimental design.
Small animal PET imaging Animals were imaged with 18 F-FDG and 18 F-FGln (24 hours apart to allow complete decay of radiotracer) by injecting 200 mCi of the radiotracer into the lateral tail vein. PET imaging was performed using a dedicated small-animal microPET scanner (Concorde Microsystems) under 2% isoflurane anesthesia, with the tumors centered in the field of view. Dynamic imaging was performed by obtaining 60-min acquisitions with an energy window of 350 to 750 keV with a coincidence timing window of 6 ns. For static imaging, acquisitions were collected 0.5, 1, and 2 hours after injection. In each animal, the MRI and PET images were directly compared. Region-of-interest (ROI) analysis of the acquired images was performed using ASI Pro software (Siemens) in a nonblinded manner, and the observed maximum pixel value was represented as percent-injected dose/cubic centimeter (%ID/cc). Tumorto-brain ratios were determined by normalizing tumor uptake to surrounding brain uptake. F-FGln was performed as described (8, 28) . Briefly, the radiolabeling procedure was similar except that the radiolabeling was performed at 90°C, and the final compound (in saline) was passed through a C 18 cartridge and AG11A8 resin to formulate the final solution for injection. The purity of 18 F-FGln was analyzed with a chiral column (Chirex 3126 D-penicillamine, 1 mM CuSO 4 solution, 1 ml/min). For human subjects, 18 F-FGln was manufactured at the MSKCC Radiochemistry and Molecular Probe Core Facility pursuant to an Investigational New Drug Application (IND) acknowledged by the United States FDA. Every batch of final drug product was tested to assure conformance to the drug product acceptance specifications, which included radiochemical purity (≥80%) and identity, residual solvent content, endotoxin content, radionuclidic identity, pH, and appearance. A total of 125 MBq was adequate for imaging the brain ROI and provided satisfactory PET image quality and count statistics. , and 160 min after injection, using a Discovery DSTE PET-computed tomography (CT) scanner (GE Healthcare) with the patient supine on the scanner bed. After a scout x-ray, CT data were acquired with 140 kVp; 70 mA; pitch of 1.75:1; reconstructed slice thickness of 3.75 mm; 0.8 s per rotation. CT data were reconstructed in a 512 × 512 matrix using a filtered back-projection algorithm. PET emission scans were acquired starting at the proximal thigh region and ending at the head region; emission scanning specifically of the brain tumor field of view shown was acquired as a single bed position of 35-min duration in three-dimensional mode. PET images were reconstructed using an ordered subset expectation maximization iterative algorithm. PET/CT scans obtained at the 60-and 150-min postinjection time points also spanned thighs to skull using the same x-ray/CT and PET emission data acquisitions and reconstructions. PET emission data were reconstructed using an ordered subset expectation maximization iterative algorithm. Emission data were corrected for random detector inhomogeneity, scatter, attenuation, dead time, and decay. PET, CT, and fusion PET-CT images shown were generated for display using an integrated GE PACS AW Suite Workstation (GE Healthcare). PET data were analyzed using HERMES workstation (Hermes Medical Solutions).
Statistical analysis
Statistical analyses were performed in consultation with the Sloan Kettering biostatistics facility. Data are represented as means ± SEM unless specified otherwise. Graphs were plotted and statistical analyses were performed using Prism software (version 6, GraphPad). All statistical tests were two-sided. Unpaired, two-tailed Student's t test or one-way ANOVA followed by post hoc Bonferroni, Dunnett's, or Tukey multiple comparison analysis was used to analyze data. Wilcoxon matched pairs signed-rank t test was used when the same parameter was assessed in the same animal in any given experiment (chemo/radiation therapy when the same animal was imaged with a given radioligand before and after treatment). Data were considered significant if P values were less than 0.05 (95% confidence intervals). The original data and P values are provided in tables S6 and S7.
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